A clinical stage biopharmaceutical company with a Phase 3-ready program in Alzheimer’s disease and a discovery platform of small molecules for the inhibition of protein misfolding in neurodegenerative disorders
Lead Underwriter
ThinkEquity, a division of Fordham Financial Management, Inc